Complete metabolic response to combined BRAF/MEK inhibition (dabrafenib-trametinib) in BRAF V600E-mutated metastatic parotid adenocarcinoma: A case report

Oral Oncology Reports · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles